How many clinical trials are there for kisspeptin clinical formulations?

36 clinical trials are currently active, completed, or in development for kisspeptin formulations. These trials span reproductive disorders, metabolic applications, and formulation optimization. You can search for active trials on [ClinicalTrials.gov](https://clinicaltrials.gov) using the search term 'kisspeptin.'

What does evidence grade B mean for kisspeptin?

Grade B indicates moderate evidence: multiple human studies showing biological activity or efficacy, but with limitations like smaller sample sizes or mixed results. It's higher than preliminary (Grade C) but lower than robust approval-level evidence (Grade A). Kisspeptin has moved beyond animal studies but isn't yet supported by the volume of large trials typical of approved drugs.

Is kisspeptin approved by the FDA?

No. Kisspeptin clinical formulations are not approved by the FDA, EMA, or Health Canada. The compound is investigational, meaning clinical trials are ongoing but regulatory approval has not been granted. Only research-grade or clinical trial access applies.

What are the main research focuses for kisspeptin trials?

The majority of trials focus on reproductive function—hypogonadism, infertility, and amenorrhea. Secondary areas include metabolic and energy regulation. Research indicates kisspeptin activates the reproductive hormone cascade (GnRH → LH/FSH), but long-term efficacy and optimal dosing regimens are still being investigated.

What are the main gaps in kisspeptin research?

Key gaps include: long-term safety and efficacy data (most trials are short-term), optimal formulation and delivery (peptides are inherently challenging to deliver), patient stratification (who responds best?), and head-to-head comparisons to approved treatments like GnRH agonists. Metabolic applications also need larger, controlled trials.

Kisspeptin Clinical Formulations: Research Evidence & Trials

Kisspeptin clinical formulations represent an investigational compound under active study for reproductive and metabolic applications. With 36 clinical trials currently underway or completed, kisspeptin has accumulated a B-grade evidence base—meaning there's meaningful research support, but key questions remain unanswered. Unlike approved therapeutics, kisspeptin formulations are not yet authorized by the FDA, EMA, or Health Canada. This page unpacks what the clinical trial landscape reveals, which studies matter most, and where research gaps still exist.

The Kisspeptin Research Landscape

Kisspeptin is a neuropeptide that plays a central role in regulating the reproductive axis—the hormonal signalling chain that governs reproduction. The peptide was discovered in 2003 and named after Hershey's Kisses candy (the research was conducted in Hershey, Pennsylvania). Since then, it's become a focal point for understanding and potentially modulating reproductive function.

The clinical trial pipeline tells the story: 36 active or completed clinical trials across multiple therapeutic areas. This substantial number signals genuine scientific and commercial interest—but also highlights that kisspeptin is still investigational. No single formulation has achieved regulatory approval in the US, EU, or Canada.

Evidence Grade: What B-Grade Means

Kisspeptin clinical formulations carry a B-grade evidence rating. Here's what that means in plain language:

Grade A (highest): Large, well-designed randomized controlled trials with consistent results across populations.
Grade B (moderate): Multiple studies showing efficacy or biological activity, but with some limitations—smaller sample sizes, fewer replications, or mixed results across trials.
Grade C: Limited or preliminary data; mostly animal studies or very small human trials.

Kisspeptin's B-grade reflects a genuine body of human research—it's beyond preliminary—but the evidence isn't yet as robust or consistent as approved drugs. This is typical for compounds in active clinical development.

Key Clinical Trial Areas

Reproductive Function & Fertility

The majority of kisspeptin trials focus on reproduction. Research indicates that kisspeptin activates GnRH (gonadotropin-releasing hormone), the master switch of the reproductive axis. Animal studies suggest kisspeptin can stimulate both LH (luteinizing hormone) and FSH (follicle-stimulating hormone), the hormones essential for egg and sperm production.

In human trials, kisspeptin administration has been shown to trigger LH secretion in healthy volunteers and patients with reproductive disorders. This forms the biological rationale for investigating kisspeptin in:

Hypogonadism (low testosterone or estrogen states)
Infertility (both male and female)
Hypothalamic amenorrhea (loss of menstruation due to low GnRH signalling)

Metabolic & Energy Regulation

Beyond reproduction, research indicates kisspeptin may influence metabolic pathways and energy homeostasis. Some trials have explored kisspeptin's role in:

Appetite and satiety signalling
Glucose metabolism
Body weight regulation

These applications are more exploratory and have fewer clinical trials than reproductive indications.

What the Published Studies Show

Pharmacokinetics & Safety

Early-phase trials established that kisspeptin peptide is well-tolerated in humans. Intravenous and intranasal formulations have been tested. Most common observations in trials:

Rapid onset of hormonal effects (minutes to hours)
Transient increases in LH and FSH
Mild, self-limiting adverse events in early trials (headache, flushing)
No severe safety signals in published trial data

However, long-term safety data—especially for chronic dosing—remains limited.

Efficacy in Reproductive Disorders

One landmark trial examined kisspeptin in patients with idiopathic hypogonadotropic hypogonadism (IHH), a condition where the reproductive axis fails to activate. Kisspeptin injection stimulated LH and testosterone in patients who had minimal response to other treatments. This suggested potential therapeutic utility in a population with genuine unmet need.

Other trials have tested kisspeptin in women with reproductive disorders, with data indicating that kisspeptin can restore or augment LH pulsatility, a hallmark of healthy reproductive function.

Challenges & Mixed Results

Not all trials have delivered straightforward successes. Some observations:

Tachyphylaxis (tolerance to repeated doses) has been reported in some formulations, limiting repeated-dose efficacy.
Delivery challenges: Kisspeptin is a peptide; oral absorption is poor, requiring injection or intranasal delivery. This complicates real-world use.
Variable responses: Not all patients respond equally to kisspeptin, suggesting heterogeneity in underlying biology or receptor sensitivity.

These findings have shaped the direction of clinical development—researchers are exploring longer-acting formulations, receptor agonists that mimic kisspeptin, and optimized dosing regimens.

Comparing Kisspeptin to Related Compounds

Kisspeptin works in the reproductive axis alongside other investigational peptides and approved drugs:

GnRH agonists: Already approved for some reproductive and oncologic conditions. They stimulate the same axis but via a different mechanism. Kisspeptin's advantage may be selectivity and fewer negative effects with long-term use.
LH-releasing peptide: Another investigational compound targeting reproductive function, with overlapping but distinct mechanisms.
Kisspeptin receptor agonists: Small-molecule compounds designed to mimic kisspeptin's effects without requiring peptide delivery. These are earlier in development but may offer better drug-like properties.

Research Gaps & Unanswered Questions

Despite 36 trials, significant questions remain:

Long-term efficacy & safety: Most trials are short-term (weeks to months). Does kisspeptin remain effective with chronic use? Are there delayed safety issues?
Optimal delivery & dosing: Peptide formulations are inherently challenging. Is intranasal delivery practical for long-term therapy? Can oral bioavailability be improved?
Patient stratification: Who responds best to kisspeptin? Genetic, hormonal, or phenotypic markers that predict response are not yet established.
Mechanism in metabolic disease: Early data on weight and glucose metabolism is intriguing but preliminary. Larger, controlled trials in metabolic disorders are needed.
Comparison to existing therapies: Head-to-head trials directly comparing kisspeptin to approved treatments (like GnRH agonists or testosterone replacement) are limited.
Receptor selectivity: Kisspeptin acts on KISS1 receptors, but cross-reactivity with other peptide receptors and long-term target engagement remain incompletely characterized.

Where Clinical Development Stands

Kisspeptin is in mid-to-late-stage clinical investigation. The B-grade evidence reflects meaningful progress—researchers have moved beyond simple proof-of-concept to testing efficacy in patient populations. However, regulatory approval is not imminent in major markets (US, EU, Canada).

The clinical trial pipeline suggests development is ongoing, particularly for:

Reproductive disorders (especially hypogonadism)
Fertility applications
Optimized formulations to overcome peptide delivery barriers

Once (or if) kisspeptin gains regulatory approval, it will likely join a portfolio of reproductive hormone therapies—competing with established GnRH agonists, testosterone replacement, and gonadotropin therapies.

The Bottom Line on Kisspeptin Evidence

Kisspeptin clinical formulations have a credible, B-grade research foundation. The 36 clinical trials represent genuine scientific momentum. Data show that kisspeptin can modulate reproductive hormones in humans and has an acceptable safety profile in short-term use. However, key questions about long-term efficacy, optimal dosing, patient selection, and practical delivery remain unanswered. The compound is investigational—not yet approved for therapeutic use—and prospective users should be aware that clinical development is ongoing.

Kisspeptin Clinical Formulations: What the Research Evidence Shows